Skip to main content
Premium Trial:

Request an Annual Quote

uBiome Files for Chapter 7 Liquidation

NEW YORK — Microbial genomics firm uBiome said today that it has filed to convert its recently declared Chapter 11 bankruptcy to a Chapter 7 liquidation.

Under Chapter 11 of the US Bankruptcy Code, uBiome can attempt to reorganize in order to preserve the business and pay its creditors over time. Under Chapter 7, the company would sell its nonexempt property and distribute the proceeds to creditors, effectively ending its operations.

San Francisco-based uBiome said it was unable to secure access to post-bankruptcy financing or settle disputes with the fiduciaries representing its unsecured creditors. As a result, it has determined that liquidation is in the best interest of the company and its shareholders, it said.

Last month, uBiome filed for Chapter 11 following the launch of a US Federal Bureau of Investigation inquiry into its billing practices, a management shake up, and the suspension of certain business activities. At the time, the company had intended to continue sales of its main commercial product, the Explorer microbiome analysis kit.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.